Company Analysis Alphamab Oncology
1. Summary
Advantages
- Price (2.66 HK$) is less than fair price (6.2 HK$)
- Current debt level 16.16% is below 100% and has decreased over 5 years from 121.62%.
Disadvantages
- Dividends (0%) are below the sector average (2.42%).
- The stock's return over the last year (-61.22%) is lower than the sector average (-21.45%).
- The company's current efficiency (ROE=-13.04%) is lower than the sector average (ROE=5.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Alphamab Oncology | Healthcare | Index | |
|---|---|---|---|
| 7 days | -40.9% | -0.3% | -1% |
| 90 days | 10.4% | 13.6% | 9.2% |
| 1 year | -61.2% | -21.5% | 8.4% |
9966 vs Sector: Alphamab Oncology has significantly underperformed the "Healthcare" sector by -39.77% over the past year.
9966 vs Market: Alphamab Oncology has significantly underperformed the market by -69.66% over the past year.
Stable price: 9966 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 9966 with weekly volatility of -1.18% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.66 HK$) is lower than the fair price (6.2 HK$).
Price significantly below the fair price: The current price (2.66 HK$) is 133.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (35.42).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (26.77).
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.27) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (3.27) is higher than that of the market as a whole (-11.93).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (25.02) is higher than that of the sector as a whole (7.59).
P/S vs Market: The company's P/S indicator (25.02) is higher than that of the market as a whole (2.78).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-25.08) is lower than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (-25.08) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -14.94% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-14.94%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-13.04%) is lower than that of the sector as a whole (5.19%).
ROE vs Market: The company's ROE (-13.04%) is lower than that of the market as a whole (6.28%).
5.5. ROA
ROA vs Sector: The company's ROA (-9.9%) is lower than that of the sector as a whole (3.47%).
ROA vs Market: The company's ROA (-9.9%) is lower than that of the market as a whole (3.38%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '2.42%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
